Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 6/20 | 0.49 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | KDM5A | P29375 | 2/20 | 0.41 |
| ▸ | DGKA | P23743 | 1/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | POLA1 | P09884 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3885211 | 0.98 | DNM1 (0.46) | DNM1NAAAKDM5ADGKAS1PR2 | |
| SCHEMBL254321 | 0.96 | DNM1 (0.44) | DNM1NAAAKDM5ADGKAS1PR2 | |
| SCHEMBL11412630 | 0.86 | DNM1 (0.56) | DNM1KDM5ADGKALMNA | |
| SCHEMBL31494293 | 0.83 | ALDH1A1 (0.39) | DNM1NAAA | |
| SCHEMBL31190462 | 0.82 | DNM1 (0.60) | DNM1DGKALMNAPOLBPOLA1 | |
| SCHEMBL25211926 | 0.82 | NAAA (0.50) | DNM1NAAAKDM5ADGKALMNA | |
| SCHEMBL25198827 | 0.82 | NAAA (0.50) | DNM1NAAAKDM5ADGKALMNA | |
| SCHEMBL11323157 | 0.82 | DNM1 (0.44) | DNM1KDM5AS1PR2S1PR1S1PR3 | |
| SCHEMBL25196488 | 0.82 | NAAA (0.50) | DNM1NAAAKDM5ADGKALMNA | |
| SCHEMBL25218755 | 0.82 | NAAA (0.50) | DNM1NAAAKDM5ADGKALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11690826-B2 | Methods for treating demodex blepharitis using lotilaner formulations | TARSUS PHARMACEUTICALS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20220354829-A1 | METHODS FOR TREATING OCULAR DEMODEX USING SPINOSAD FORMULATIONS | BIOPHARMA CREDIT PLC (GB) | 2022-11-10 | — | — | US | disclosed |
| US-20130317462-A1 | TRANSDERMAL DELIVERY SYSTEM FOR HORMONES AND STEROIDS | ACRUX DDS PTY LTD. (AU) | 2013-11-28 | — | — | US | disclosed |
| US-20080319370-A1 | Method and System for Transdermal Drug Delivery | ACRUX DDS PTY LTD. | 2008-12-25 | — | — | US | disclosed |
| EP-1778216-A1 | FORMULATION FOR STIMULATING HAIR GROWTH | Warner-Lambert Company LLC (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006011046-A1 | FORMULATION FOR STIMULATING HAIR GROWTH | WARNER-LAMBERT COMPANY LLC (US) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130317462-A1 | TRANSDERMAL DELIVERY SYSTEM FOR HORMONES AND STEROIDS | SHBG, PGR, NR5A1 | DNM1 2969/4885NAAA 3106/4885KDM5A 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.